Combined PARP and ATR Inhibition Potentiates Genome Instability and Cell Death in ATM-Deficient Cancer Cells

Scientists showed that olaparib combined synergistically with the synergistically with the ataxia-telangiectasia mutated and Rad3-related-inhibitor AZD6738, in vitro, leading to selective cell death in cell death in ataxia-telangiectasia mutated-deficient cells.
[Oncogene]
Full Article

Continue reading “Combined PARP and ATR Inhibition Potentiates Genome Instability and Cell Death in ATM-Deficient Cancer Cells”

Bookmark

No account yet? Register

0
Share

DNMT1: A Key Drug Target in Triple-Negative Breast Cancer

The author presents and discusses the oncogenic functions rendered by DNA methyltransferase 1 (DNMT1) in triple negative breast cancer, and DNMT1 inhibitors targeting TNBC cells.
[Seminars in Cancer Biology]
Abstract

Continue reading “DNMT1: A Key Drug Target in Triple-Negative Breast Cancer”

Bookmark

No account yet? Register

0
Share

ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase III E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2 Breast Cancer

Syndax Pharmaceuticals, Inc. announced receipt of the final results of E2112, that evaluated the investigational compound entinostat, Syndax’s class I HDAC inhibitor, plus exemestane in patients with advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer who have progressed on a non-steroidal aromatase inhibitor.
[Syndax]
Press Release

Continue reading “ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase III E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2 Breast Cancer”

Bookmark

No account yet? Register

0
Share

Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer

Daiichi Sankyo Company, Limited announced the launch of ENHERTU® (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate, in Japan for the treatment of patients with HER2 positive unresectable or recurrent breast cancer after prior chemotherapy.
[Daiichi-Sankyo]
Press Release

Continue reading “Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer”

Bookmark

No account yet? Register

0
Share
Share